7Other operating income and expenses

Other operating income includes income from litigation cases, government grants and incentives, as well as recharges to third parties not qualifying as sales from customers. Other operating income included income from charges to the discontinued operation Applicator System division (later renamed medmix) for corporate support functions and centrally procured indirect spend utilized by medmix of CHF 1.6 million (first half of 2022: CHF 4.6 million). 

In the first half of 2023, the total gain from deconsolidation primarily included a gain of CHF 8.0 million from the deconsolidation of four Russian legal entities (see note 5). The total gain and loss from deconsolidation in the first six months includes a net gain from the reclassification of currency translation adjustments of CHF 10.7 million and a gain of CHF 0.6 million from the reclassification of cash flow hedge reserves. 

In the first half of 2022, the loss from deconsolidation of subsidiaries comprised a loss from deconsolidation of subsidiaries of CHF 6.2 million resulting from the deconsolidation of two subsidiaries in Poland and a loss of CHF 0.6 million from the disposal of a subsidiary in Brazil. The loss from deconsolidation of subsidiaries includes a loss from reclassification of currency translation differences amounting to CHF 2.2 million (see note 5).

In the first half of 2023, the group recognized impairments of CHF 0.0 million (first half of 2022: CHF 36.4 million). In the first half of 2022, the group recorded impairments of CHF 32.2 million on goodwill, other intangible assets, and property, plant and equipment in connection with the classification of the business in Russia as held for sale and the write-down to fair value less costs to sell and CHF 4.2 million based on performed impairment tests on production machines and facilities.